The DOI matches its Crossref record; 252 of the 252 references it cites were found in a registry or an index.
Brain health: time matters in multiple sclerosis
Open accessAbstract
INTRODUCTION: We present international consensus recommendations for improving diagnosis, management and treatment access in multiple sclerosis (MS). Our vision is that these will be used widely among those committed to creating a better future for people with MS and their families. METHODS: Structured discussions and literature searches conducted in 2015 examined the personal and economic impact of MS, current practice in diagnosis, treatment and management, definitions of disease activity and barriers to accessing disease-modifying therapies (DMTs). RESULTS: Delays often occur before a person with symptoms suggestive of MS sees a neurologist. Campaigns to raise awareness of MS are needed, as are initiatives to improve access to MS healthcare professionals and services. We recommend a clear treatment goal: to maximize neurological reserve, cognitive function and physical function by reducing disease activity. Treatment should start early, with DMT and lifestyle measures. All parameters that predict relapses and disability progression should be included in the definition of disease activity and monitored regularly when practical. On suboptimal control of disease activity, switching to a DMT with a different mechanism of action should be considered. A shared decision-making process that embodies dialogue and considers all appropriate DMTs should be implemented. Monitoring data should be recorded formally in registries to generate real-world evidence. In many jurisdictions, access to DMTs is limited. To improve treatment access the relevant bodies should consider all costs to all parties when conducting economic evaluations and encourage the continuing investigation, development and use of cost-effective therapeutic strategies and alternative financing models. CONCLUSIONS: The consensus findings of an international author group recommend a therapeutic strategy based on proactive monitoring and shared decision-making in MS. Early diagnosis and improved treatment access are also key components.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rogers, E. M., Singhal, A., & Quinlan, M. M. (2019) · An Integrated Approach to Communication Theory and Research · doi:10.4324/9780203710753-35 · Cited by 37,322
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H., Kappos, L., Lublin, F. D., Metz, L. M., McFarland, H. F., O'Connor, P. W., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20703 · Cited by 5,017
Compston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
What is cognitive reserve? Theory and research application of the reserve concept
STERN, Y. (2002) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617702813248 · Cited by 3,951
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Self-citationDefining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Self-citationOral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Economic Costs of Diabetes in the U.S. in 2012
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc12-2625 · Cited by 2,163
Treating rheumatoid arthritis to target: recommendations of an international task force
Smolen, J. S., Aletaha, D., Bijlsma, J. W. J., Breedveld, F. C., Boumpas, D., Burmester, G., Combe, B., Cutolo, M., de Wit, M., Dougados, M., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.123919 · Cited by 2,100
Compston, A., & Coles, A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08220-x · Cited by 1,743
Jacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P. J., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,501
The economic cost of brain disorders in Europe
Olesen, J., Gustavsson, A., Svensson, M., Wittchen, H. ‐., Jönsson, B., on behalf of the CDBE2010 study group, & the European Brain Council (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03590.x · Cited by 1,481
Schumacher, G. A., Beebe, G., Kibler, R. F., Kurland, L. T., Kurtzke, J. F., McDowell, F., Nagler, B., Sibley, W. A., Tourtellotte, W. W., & Willmon, T. L. (1965) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1965.tb20235.x · Cited by 1,438
Grigor, C., Capell, H., Stirling, A., McMahon, A. D., Lock, P., Vallance, R., Porter, D., & Kincaid, W. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16676-2 · Cited by 1,435
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdova, E., Kita, M., Yang, M., Raghupathi, K., Novas, M., Sweetser, M. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206328 · Cited by 1,355
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,344
Relapses and Progression of Disability in Multiple Sclerosis
Confavreux, C., Vukusic, S., Moreau, T., & Adeleine, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432001 · Cited by 1,309
Diagnostic criteria for multiple sclerosis
Poser, C. M., & Brinar, V. V. (2001) · Clinical Neurology and Neurosurgery · doi:10.1016/s0303-8467(00)00125-6 · Cited by 1,283
Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205
Self-citationColes, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61768-1 · Cited by 1,198
Braman, S. S. (2006) · Chest · doi:10.1378/chest.130.1_suppl.4s · Cited by 1,176
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, O., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,053
Di Benedetto, C. A. (2015) · Wiley Encyclopedia of Management · doi:10.1002/9781118785317.weom130016 · Cited by 1,051
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802670 · Cited by 1,017
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
O'Connor, P., Wolinsky, J. S., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Benzerdjeb, H., Truffinet, P., Wang, L., Miller, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014656 · Cited by 990
Fisniku, L. K., Brex, P. A., Altmann, D. R., Miszkiel, K. A., Benton, C. E., Lanyon, R., Thompson, A. J., & Miller, D. H. (2008) · Brain · doi:10.1093/brain/awm329 · Cited by 897
Cognitive dysfunction in multiple sclerosis.: II. Impact on employment and social functioning
Rao, S. M., Leo, G. J., Ellington, L., Nauertz, T., Bernardin, L., & Unverzagt, F. (1991) · Neurology · doi:10.1212/wnl.41.5.692 · Cited by 890
Primary-progressive multiple sclerosis
Miller, D. H., & Leary, S. M. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70243-0 · Cited by 818
International MS Genetics Consortium, De Jager, P. L., Jia, X., Wang, J., de Bakker, P. I. W., Ottoboni, L., Aggarwal, N. T., Piccio, L., Raychaudhuri, S., Tran, D., et al. (2009) · Nature Genetics · doi:10.1038/ng.401 · Cited by 800
Kuhlmann, T. (2002) · Brain · doi:10.1093/brain/awf235 · Cited by 775
Weinstein, M. C., Torrance, G., & McGuire, A. (2009) · Value in Health · doi:10.1111/j.1524-4733.2009.00515.x · Cited by 748
Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis
Simpson, S., Blizzard, L., Otahal, P., Van der Mei, I., & Taylor, B. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2011.240432 · Cited by 718
Scalfari, A., Neuhaus, A., Degenhardt, A., Rice, G. P., Muraro, P. A., Daumer, M., & Ebers, G. C. (2010) · Brain · doi:10.1093/brain/awq118 · Cited by 711
Epidemiology and costs of chronic obstructive pulmonary disease
Chapman, K. R., Mannino, D. M., Soriano, J. B., Vermeire, P. A., Buist, A. S., Thun, M. J., Connell, C., Jemal, A., Lee, T. A., Miravitlles, M., et al. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00024505 · Cited by 704
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., Montalban, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237641.33768.8d · Cited by 681
Incidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome
Okuda, D. T., Mowry, E. M., Beheshtian, A., Waubant, E., Baranzini, S. E., Goodin, D. S., Hauser, S. L., & Pelletier, D. (2009) · Neurology · doi:10.1212/01.wnl.0000335764.14513.1a · Cited by 642
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Miller, D., Barkhof, F., Montalban, X., Thompson, A., & Filippi, M. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70071-5 · Cited by 594
Comi, G., Martinelli, V, Rodegher, M., Moiola, L., Bajenaru, O., Carra, A., Elovaara, I., Fazekas, F., Hartung, H., Hillert, J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61259-9 · Cited by 592
PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS
The PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group, & the University of British Columbia MS/MRI Analysis Group (2001) · Neurology · doi:10.1212/wnl.56.12.1628 · Cited by 571
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., Montalban, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.11.003 · Cited by 549
Twin concordance and sibling recurrence rates in multiple sclerosis
Willer, C. J., Dyment, D. A., Risch, N. J., Sadovnick, A. D., Ebers, G. C., & The Canadian Collaborative Study Group§§ (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1932604100 · Cited by 532
Benedict, R. H. B., Wahlig, E., Bakshi, R., Fishman, I., Munschauer, F., Zivadinov, R., & Weinstock-Guttman, B. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.12.009 · Cited by 528
Evidence of Axonal Damage in the Early Stages of Multiple Sclerosis and Its Relevance to Disability
De Stefano, N., Narayanan, S., Francis, G. S., Arnaoutelis, R., Tartaglia, M. C., Antel, J. P., Matthews, P. M., & Arnold, D. L. (2001) · Archives of Neurology · doi:10.1001/archneur.58.1.65 · Cited by 505
Kappos, L., Moeri, D., Radue, E. W., Schoetzau, A., Schweikert, K., Barkhof, F., Miller, D., Guttmann, C. R., Weiner, H. L., Gasperini, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)03053-0 · Cited by 499
Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis
Marrie, R. A., Rudick, R., Horwitz, R., Cutter, G., Tyry, T., Campagnolo, D., & Vollmer, T. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6b125 · Cited by 479
Self-citationAxonal pathology in multiple sclerosis: relationship to neurologic disability
Trapp, B. D., Ransohoff, R., & Rudick, R. (1999) · Current Opinion in Neurology · doi:10.1097/00019052-199906000-00008 · Cited by 475
Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results
Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group* (2001) · Neurology · doi:10.1212/wnl.56.11.1496 · Cited by 475
PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS
Francis, G., Hughes, R. A., King, J. O., Mitchell, P. I., Joubert, J.-M., McLeod, J., Parker, G., Pollard, J. D., Sindic, C., Duprez, T. P. J., et al. (2001) · DIAL (Catholic University of Leuven) · doi:10.25405/ncl.34089345 · Cited by 472
Havrdova, E., Galetta, S., Hutchinson, M., Stefoski, D., Bates, D., Polman, C. H., O'Connor, P. W., Giovannoni, G., Phillips, J. T., Lublin, F. D., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70021-3 · Cited by 471
Self-citationRandomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results
Li, D. K. B., Zhao, G. J., Paty, D. W., & the University of British Columbia MS/MRI Analysis Research Group and the SPECTRIMS Study Group* (2001) · Neurology · doi:10.1212/wnl.56.11.1505 · Cited by 458
Levin, L. I. (2005) · JAMA · doi:10.1001/jama.293.20.2496 · Cited by 448
Smolen, J. S., Braun, J., Dougados, M., Emery, P., FitzGerald, O., Helliwell, P., Kavanaugh, A., Kvien, T. K., Landewé, R., Luger, T., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203419 · Cited by 447
Lobentanz, I. S., Asenbaum, S., Vass, K., Sauter, C., Klosch, G., Kollegger, H., Kristoferitsch, W., & Zeitlhofer, J. (2004) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2004.00257.x · Cited by 439
Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study
The North American Study Group on Interferon beta-1b in Secondary Progressive MS (2004) · Neurology · doi:10.1212/01.wnl.0000146958.77317.3e · Cited by 423
Effect of relapses on development of residual deficit in multiple sclerosis
Lublin, F. D., Baier, M., & Cutter, G. (2003) · Neurology · doi:10.1212/01.wnl.0000096175.39831.21 · Cited by 421
Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort
Rotstein, D. L., Healy, B. C., Malik, M. T., Chitnis, T., & Weiner, H. L. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.3537 · Cited by 418
Primary infection with the Epstein‐Barr virus and risk of multiple sclerosis
Levin, L. I., Munger, K. L., O'Reilly, E. J., Falk, K. I., & Ascherio, A. (2010) · Annals of Neurology · doi:10.1002/ana.21978 · Cited by 404
Benefit of interferon β-1a on MSFC progression in secondary progressive MS
Cohen, J. A., Cutter, G. R., Fischer, J. S., Goodman, A. D., Heidenreich, F. R., Kooijmans, M. F., Sandrock, A. W., Rudick, R. A., Simon, J. H., Simonian, N. A., et al. (2002) · Neurology · doi:10.1212/wnl.59.5.679 · Cited by 402
Schembri, M. (2016) · European Society of Radiology · doi:10.1594/ecr2016/c-1350 · Cited by 367
Costs and quality of life of patients with multiple sclerosis in Europe
Kobelt, G. (2006) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.090365 · Cited by 363
Self-citationGenetic variability of human brain size and cortical gyral patterns
Bartley, A. (1997) · Brain · doi:10.1093/brain/120.2.257 · Cited by 355
The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?
Weiner, H. L. (2009) · Annals of Neurology · doi:10.1002/ana.21640 · Cited by 344
Radiologically isolated syndrome: 5-year risk for an initial clinical event
Okuda, D. T., Siva, A., Kantarci, O., Inglese, M., Katz, I., Tutuncu, M., Keegan, B. M., Donlon, S., Hua, L. H., Vidal-Jordana, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090509 · Cited by 339
Self-citationBrain atrophy and lesion load predict long term disability in multiple sclerosis
Popescu, V., Agosta, F., Hulst, H. E., Sluimer, I. C., Knol, D. L., Sormani, M. P., Enzinger, C., Ropele, S., Alonso, J., Sastre-Garriga, J., et al. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304094 · Cited by 331
Self-citationSwanton, J. K., Rovira, A., Tintore, M., Altmann, D. R., Barkhof, F., Filippi, M., Huerga, E., Miszkiel, K. A., Plant, G. T., Polman, C., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70176-x · Cited by 330
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
De Stefano, N., Giorgio, A., Battaglini, M., Rovaris, M., Sormani, M. P., Barkhof, F., Korteweg, T., Enzinger, C., Fazekas, F., Calabrese, M., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e24136 · Cited by 321
Self-citationThe rising prevalence and changing age distribution of multiple sclerosis in Manitoba
Marrie, R. A., Yu, N., Blanchard, J., Leung, S., & Elliott, L. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cf6ec0 · Cited by 307
Clinical Relevance of Brain Volume Measures in Multiple Sclerosis
De Stefano, N., Airas, L., Grigoriadis, N., Mattle, H. P., O’Riordan, J., Oreja-Guevara, C., Sellebjerg, F., Stankoff, B., Walczak, A., Wiendl, H., et al. (2014) · CNS Drugs · doi:10.1007/s40263-014-0140-z · Cited by 301
Miller, A. E., Wolinsky, J. S., Kappos, L., Comi, G., Freedman, M. S., Olsson, T. P., Bauer, D., Benamor, M., Truffinet, P., & O'Connor, P. W. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70191-7 · Cited by 300
Sormani, M. P., Arnold, D. L., & De Stefano, N. (2014) · Annals of Neurology · doi:10.1002/ana.24018 · Cited by 297
Self-citationSmoking and Multiple Sclerosis: An Updated Meta-Analysis
Handel, A. E., Williamson, A. J., Disanto, G., Dobson, R., Giovannoni, G., & Ramagopalan, S. V. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016149 · Cited by 296
Self-citationEmployment in multiple sclerosis: Exiting and re-entering the work force
Julian, L. J., Vella, L., Vollmer, T., Hadjimichael, O., & Mohr, D. C. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0910-y · Cited by 294
Self-citationOnset of secondary progressive phase and long-term evolution of multiple sclerosis
Scalfari, A., Neuhaus, A., Daumer, M., Muraro, P. A., & Ebers, G. C. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304333 · Cited by 291
Dalton, C. M., Brex, P. A., Miszkiel, K. A., Hickman, S. J., MacManus, D. G., Plant, G. T., Thompson, A. J., & Miller, D. H. (2002) · Annals of Neurology · doi:10.1002/ana.10240 · Cited by 290
Miller, A., & Dishon, S. (2006) · Quality of Life Research · doi:10.1007/s11136-005-0891-6 · Cited by 288
Costs and quality of life in multiple sclerosis: A cross-sectional study in the United States
Kobelt, G., Berg, J., Atherly, D., & Hadjimichael, O. (2006) · Neurology · doi:10.1212/01.wnl.0000218309.01322.5c · Cited by 286
Self-citationMRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials
Sormani, M. P., & Bruzzi, P. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70103-0 · Cited by 278
Self-citationNew natural history of interferon‐β–treated relapsing multiple sclerosis
Trojano, M., Pellegrini, F., Fuiani, A., Paolicelli, D., Zipoli, V., Zimatore, G. B., Di Monte, E., Portaccio, E., Lepore, V., Livrea, P., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21102 · Cited by 270
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial
Coles, A. J., Fox, E., Vladic, A., Gazda, S. K., Brinar, V., Selmaj, K. W., Skoromets, A., Stolyarov, I., Bass, A., Sullivan, H., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31824e8ee7 · Cited by 268
Shirani, A., Zhao, Y., Karim, M. E., Evans, C., Kingwell, E., van der Kop, M. L., Oger, J., Gustafson, P., Petkau, J., & Tremlett, H. (2012) · JAMA · doi:10.1001/jama.2012.7625 · Cited by 263
Scoring treatment response in patients with relapsing multiple sclerosis
Sormani, M., Rio, J., Tintorè, M., Signori, A., Li, D., Cornelisse, P., Stubinski, B., Stromillo, M., Montalban, X., & De Stefano, N. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458512460605 · Cited by 262
Self-citationTen arguments for a societal perspective in the economic evaluation of medical innovations
Jönsson, B. (2009) · The European Journal of Health Economics · doi:10.1007/s10198-009-0173-2 · Cited by 262
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
Hartung, D. M., Bourdette, D. N., Ahmed, S. M., & Whitham, R. H. (2015) · Neurology · doi:10.1212/wnl.0000000000001608 · Cited by 261
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS
Kappos, L., Traboulsee, A., Constantinescu, C., Erälinna, J. P., Forrestal, F., Jongen, P., Pollard, J., Sandberg-Wollheim, M., Sindic, C., Stubinski, B., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237994.95410.ce · Cited by 257
Self-citationEstablishing pathological cut-offs of brain atrophy rates in multiple sclerosis
De Stefano, N., Stromillo, M. L., Giorgio, A., Bartolozzi, M. L., Battaglini, M., Baldini, M., Portaccio, E., Amato, M. P., & Sormani, M. P. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-309903 · Cited by 256
Self-citationMRI criteria for MS in patients with clinically isolated syndromes
Montalban, X., Tintoré, M., Swanton, J., Barkhof, F., Fazekas, F., Filippi, M., Frederiksen, J., Kappos, L., Palace, J., Polman, C., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cec45c · Cited by 252
Filippi, M., Rovaris, M., Inglese, M., Barkhof, F., De Stefano, N., Smith, S., & Comi, G. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17271-1 · Cited by 251
Survival in MS: A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial
Goodin, D. S., Reder, A. T., Ebers, G. C., Cutter, G., Kremenchutzky, M., Oger, J., Langdon, D., Rametta, M., Beckmann, K., DeSimone, T. M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182535cf6 · Cited by 249
Bryant, J., Clegg, A., Nicholson, T., McIntyre, L., De Broe, S., Gerard, K., & Waugh, N. (2001) · Health Technology Assessment · doi:10.3310/hta5010 · Cited by 246
Butzkueven, H., Chapman, J., Cristiano, E., Grand’Maison, F., Hoffmann, M., Izquierdo, G., Jolley, D., Kappos, L., Leist, T., Pöhlau, D., et al. (2006) · Multiple Sclerosis Journal · doi:10.1177/1352458506070775 · Cited by 245
Self-citationThe natural history of secondary progressive multiple sclerosis
Koch, M., Kingwell, E., Rieckmann, P., Tremlett, H., & Neurologists, U. M. C. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.208173 · Cited by 241
New diagnostic criteria for multiple sclerosis: Application in first demyelinating episode
Tintoré, M., Rovira, A., Río, J., Nos, C., Grivé, E., Sastre-Garriga, J., Pericot, I., Sánchez, E., Comabella, M., & Montalban, X. (2003) · Neurology · doi:10.1212/wnl.60.1.27 · Cited by 237
A prospective study of patterns of fatigue in multiple sclerosis
Lerdal, A., Gulowsen Celius, E., Krupp, L., & Dahl, A. A. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.01974.x · Cited by 232
Effect of comorbidity on mortality in multiple sclerosis
Marrie, R. A., Elliott, L., Marriott, J., Cossoy, M., Blanchard, J., Leung, S., & Yu, N. (2015) · Neurology · doi:10.1212/wnl.0000000000001718 · Cited by 229
Intracranial capacity and brain volumes are associated with cognition in healthy elderly men
MacLullich, A. M. J., Ferguson, K. J., Deary, I. J., Seckl, J. R., Starr, J. M., & Wardlaw, J. M. (2002) · Neurology · doi:10.1212/wnl.59.2.169 · Cited by 228
Sormani, M. P., Bonzano, L., Roccatagliata, L., Cutter, G. R., Mancardi, G. L., & Bruzzi, P. (2009) · Annals of Neurology · doi:10.1002/ana.21606 · Cited by 223
Self-citationScolding, N., Barnes, D., Cader, S., Chataway, J., Chaudhuri, A., Coles, A., Giovannoni, G., Miller, D., Rashid, W., Schmierer, K., et al. (2015) · Practical Neurology · doi:10.1136/practneurol-2015-001139 · Cited by 222
Self-citationComi, G., De Stefano, N., Freedman, M. S., Barkhof, F., Polman, C. H., Uitdehaag, B. M., Casset-Semanaz, F., Hennessy, B., Moraga, M. S., Rocak, S., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70262-9 · Cited by 220
Khatri, B., Barkhof, F., Comi, G., Hartung, H.-P., Kappos, L., Montalban, X., Pelletier, J., Stites, T., Wu, S., Holdbrook, F., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70099-0 · Cited by 218
Mobility Device Use in the United States
Kang, T., & LaPlante, M. P. (2003) · Cited by 217
Economic Burden of Multiple Sclerosis: A Systematic Review of the Literature
Naci, H., Fleurence, R., Birt, J., & Duhig, A. (2010) · PharmacoEconomics · doi:10.2165/11532230-000000000-00000 · Cited by 215
Prakash, R. S., Snook, E. M., Motl, R. W., & Kramer, A. F. (2010) · Brain Research · doi:10.1016/j.brainres.2009.06.063 · Cited by 211
Abstract #100: Acth-Secreting Pheochromocytoma
Kalia-Reynolds, M., Giordano, J., Kalia-Reynolds, I., & Houston, C. (2015) · Endocrine Practice · doi:10.1016/s1530-891x(20)42300-6 · Cited by 208
Brain reserve and cognitive reserve in multiple sclerosis: What you’ve got and how you use it
Sumowski, J. F., Rocca, M. A., Leavitt, V. M., Riccitelli, G., Comi, G., DeLuca, J., & Filippi, M. (2013) · Neurology · doi:10.1212/wnl.0b013e318296e98b · Cited by 207
Menzin, J., Caon, C., Nichols, C., White, L. A., Friedman, M., & Pill, M. W. (2013) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2013.19.s1.s24 · Cited by 204
Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations
Freedman, M. S., Selchen, D., Arnold, D. L., Prat, A., Banwell, B., Yeung, M., Morgenthau, D., & Lapierre, Y. (2013) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100014244 · Cited by 202
Brain reserve and cognitive reserve protect against cognitive decline over 4.5 years in MS
Sumowski, J. F., Rocca, M. A., Leavitt, V. M., Dackovic, J., Mesaros, S., Drulovic, J., DeLuca, J., & Filippi, M. (2014) · Neurology · doi:10.1212/wnl.0000000000000433 · Cited by 202
Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial
Kappos, L., O'Connor, P., Radue, E.-W., Polman, C., Hohlfeld, R., Selmaj, K., Ritter, S., Schlosshauer, R., von Rosenstiel, P., Zhang-Auberson, L., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001462 · Cited by 189
Telerehabilitation for persons with multiple sclerosis
Khan, F., Amatya, B., Kesselring, J., & Galea, M. P. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010508.pub2 · Cited by 185
Epidemiology of Multiple Sclerosis in Iran: A Systematic Review
Etemadifar, M., Sajjadi, S., Nasr, Z., Firoozeei, T. S., Abtahi, S.-H., Akbari, M., & Fereidan-Esfahani, M. (2013) · European Neurology · doi:10.1159/000355140 · Cited by 183
Predictors of long‐term outcome in multiple sclerosis patients treated with interferon beta
Bermel, R. A., You, X., Foulds, P., Hyde, R., Simon, J. H., Fisher, E., & Rudick, R. A. (2013) · Annals of Neurology · doi:10.1002/ana.23758 · Cited by 180
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
Butzkueven, H., Kappos, L., Pellegrini, F., Trojano, M., Wiendl, H., Patel, R. N., Zhang, A., Hotermans, C., Belachew, S., & on behalf of the TYSABRI Observational Program (TOP) Investigators (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-306936 · Cited by 178
Self-citationSerum neurofilament light chain levels are increased in patients with a clinically isolated syndrome
Disanto, G., Adiutori, R., Dobson, R., Martinelli, V., Costa, G. D., Runia, T. F., Evdoshenko, E. P., Thouvenot, É., Trojano, M., Norgren, N., et al. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-309690 · Cited by 177
Self-citationFingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
Kuhle, J., Disanto, G., Lorscheider, J., Stites, T., Chen, Y., Dahlke, F., Francis, G., Shrinivasan, A., Radue, E.-W., Giovannoni, G., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001491 · Cited by 175
Self-citationDTI Measurements in Multiple Sclerosis: Evaluation of Brain Damage and Clinical Implications
Sbardella, E., Tona, F., Petsas, N., & Pantano, P. (2013) · Multiple Sclerosis International · doi:10.1155/2013/671730 · Cited by 172
Smoking is a risk factor for early conversion to clinically definite multiple sclerosis
Pauli, F. D., Reindl, M., Ehling, R., Schautzer, F., Gneiss, C., Lutterotti, A., O’Reilly, É., Munger, K. L., Deisenhammer, F., Ascherio, A., et al. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458508093679 · Cited by 172
Orme, M., Kerrigan, J., Tyas, D., Russell, N., & Nixon, R. (2007) · Value in Health · doi:10.1111/j.1524-4733.2006.00144.x · Cited by 170
Stangel, M., Penner, I. K., Kallmann, B. A., Lukas, C., & Kieseier, B. C. (2015) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285614560733 · Cited by 169
Barkhof, F., Scheltens, P., Frequin, S. T., Nauta, J. J., Tas, M. W., Valk, J., & Hommes, O. R. (1992) · American Journal of Roentgenology · doi:10.2214/ajr.159.5.1414773 · Cited by 165
Increasing prevalence and incidence of multiple sclerosis in South East Wales
Hirst, C. L., Ingram, G., Pickersgill, T. P., Swingler, R. J., Compston, D. A. S., & Robertson, N. P. (2008) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.144667 · Cited by 163
Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI
Sethi, V., Yousry, T. A., Muhlert, N., Ron, M., Golay, X., Wheeler-Kingshott, C., Miller, D. H., & Chard, D. T. (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303023 · Cited by 163
Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis
Kalincik, T., Horakova, D., Spelman, T., Jokubaitis, V., Trojano, M., Lugaresi, A., Izquierdo, G., Rozsa, C., Grammond, P., Alroughani, R., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24339 · Cited by 162
Self-citationRuet, A., Deloire, M., Hamel, D., Ouallet, J.-C., Petry, K., & Brochet, B. (2013) · Journal of Neurology · doi:10.1007/s00415-012-6705-1 · Cited by 162
Real‐life impact of early interferonβ therapy in relapsing multiple sclerosis
Trojano, M., Pellegrini, F., Paolicelli, D., Fuiani, A., Zimatore, G. B., Tortorella, C., Simone, I. L., Patti, F., Ghezzi, A., Zipoli, V., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21757 · Cited by 162
Kalmar, J. H., Gaudino, E. A., Moore, N. B., Halper, J., & DeLuca, J. (2008) · Neuropsychology · doi:10.1037/0894-4105.22.4.442 · Cited by 160
Rocca, M. A., Mezzapesa, D. M., Falini, A., Ghezzi, A., Martinelli, V., Scotti, G., Comı, G., & Filippi, M. (2003) · NeuroImage · doi:10.1016/s1053-8119(03)00043-0 · Cited by 158
Management of Fatigue in Persons with Multiple Sclerosis
Khan, F., Amatya, B., & Galea, M. P. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00177 · Cited by 158
Treatment of Acute Relapses in Multiple Sclerosis
Berkovich, R. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0160-7 · Cited by 154
Pittas, F., Ponsonby, A., van der Mei, I. A. F., Taylor, B. V., Blizzard, L., Groom, P., Ukoumunne, O. C., & Dwyer, T. (2009) · Journal of Neurology · doi:10.1007/s00415-009-0120-2 · Cited by 154
Improving quality of life in multiple sclerosis: an unmet need.
Zwibel, H., & Smrtka, J. (2011) · PubMed · Cited by 150
MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system
Filippi, M., & Rocca, M. A. (2005) · Journal of Neurology · doi:10.1007/s00415-005-5004-5 · Cited by 145
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis
Radue, E. W., Barkhof, F., Kappos, L., Sprenger, T., Häring, D. A., de Vera, A., von Rosenstiel, P., Bright, J. R., Francis, G., & Cohen, J. A. (2015) · Neurology · doi:10.1212/wnl.0000000000001281 · Cited by 144
Brain size, head size, and intelligence quotient in monozygotic twins
Tramo, M., Loftus, W. C., Stukel, T., Green, R. L., Weaver, J., & Gazzaniga, M. (1998) · Neurology · doi:10.1212/wnl.50.5.1246 · Cited by 143
Fingolimod after natalizumab and the risk of short-term relapse
Jokubaitis, V., Li, V., Kalinčík, T., Izquierdo, G., Hodgkinson, S. J., Alroughani, R., Lechner‐Scott, J., Lugaresi, A., Duquette, P., Girard, M., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000283 · Cited by 142
Self-citationCostello, K., Kennedy, P., & Scanzillo, J. (2008) · PubMed · Cited by 141
Freedom from disease activity in multiple sclerosis
Havrdová, E., Galetta, S. L., Stefoski, D., & Comı, G. (2010) · Neurology · doi:10.1212/wnl.0b013e3181dbb51c · Cited by 140
Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity
Breuer, J., Schwab, N., Schneider‐Hohendorf, T., Marziniak, M., Mohan, H., Bhatia, U., Groß, C. C., Clausen, B. E., Weishaupt, C., Luger, T. A., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24165 · Cited by 140
Torkildsen, N. G., Lie, S. A., Aarseth, J. H., Nyland, H., & Myhr, K.-M. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458508093890 · Cited by 138
Rudick, R. A., & Polman, C. H. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70082-1 · Cited by 137
Multiple sclerosis: diagnosis and the management of acute relapses
Leary, S. M., Porter, B., & Thompson, A. J. (2005) · Postgraduate Medical Journal · doi:10.1136/pgmj.2004.029413 · Cited by 136
SUMOWSKI, J. F., CHIARAVALLOTI, N., WYLIE, G., & DELUCA, J. (2009) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617709090912 · Cited by 132
Glanz, B. I., Healy, B. C., Rintell, D. J., Jaffin, S. K., Bakshi, R., & Weiner, H. L. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.11.004 · Cited by 124
Ebers, G. C., Traboulsee, A. L., Li, D., Langdon, D. W., Reder, A. T., Goodin, D. S., Bogumil, T., Beckmann, K., Wolf, C., Konieczny, A., et al. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.204123 · Cited by 123
Self-citationSvenningsson, A., Eva, F., Celius, E. G., Fuchs, S., Schreiber, K. I., Berkö, S., Sun, J., Penner, I., & for the TYNERGY trial investigators (2013) · PLoS ONE · doi:10.1371/journal.pone.0058643 · Cited by 119
Information provision for people with multiple sclerosis
Köpke, S., Solari, A., Khan, F., Heesen, C., & Giordano, A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008757.pub2 · Cited by 118
Pogge, T. W. (2008) · Public Health Ethics · doi:10.1093/phe/phn023 · Cited by 118
Surrogate endpoints for EDSS worsening in multiple sclerosis
Sormani, M. P., Bonzano, L., Roccatagliata, L., Mancardi, G., Uccelli, A., & Bruzzi, P. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ea15aa · Cited by 116
Self-citationHe, A. H., Spelman, T. D., Jokubaitis, V., Havrdová, E., Horáková, D., Trojano, M., Lugaresi, A., Izquierdo, G., Grammond, P., Duquette, P., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4147 · Cited by 116
Self-citationBorreani, C., Bianchi, E., Pietrolongo, E., Rossi, I., Cilia, S., Giuntoli, M., Giordano, A., Confalonieri, P. A., Lugaresi, A., Patti, F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109679 · Cited by 113
Parkin, D. (2000) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.2.144 · Cited by 113
Risks of multiple sclerosis in relatives of patients in Flanders, Belgium.
Carton, H., VLIETINCK, R. F., Debruyne, J., Keyser, J. D., D'hooghe, M. B., Loos, R. J. F., Medaer, R., Truyen, L., Yee, I. M. L., & Sadovnick, A. D. (1997) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.4.329 · Cited by 109
Functional MRI in Multiple Sclerosis
Rocca, M. A., & Filippi, M. (2007) · Journal of Neuroimaging · doi:10.1111/j.1552-6569.2007.00135.x · Cited by 107
Sumowski, J. F., Wylie, G. R., Chiaravalloti, N. D., & DeLuca, J. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e396be · Cited by 105
Evolving expectations around early management of multiple sclerosis
Gold, R., Wolinsky, J. S., Amato, M. P., & Comı, G. (2010) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285610385608 · Cited by 104
Home-based physical telerehabilitation in patients with multiple sclerosis: a pilot study.
Finkelstein, J., Lapshin, O., Castro, H. K., Cha, E., & Provance, P. G. (2008) · The Journal of Rehabilitation Research and Development · doi:10.1682/jrrd.2008.01.0001 · Cited by 101
Seasonal variation of relapse rate in multiple sclerosis is latitude dependent
Spelman, T. D., Gray, O. M., Trojano, M., Petersen, T., Izquierdo, G., Lugaresi, A., Hupperts, R., Bergamaschi, R., Duquette, P., Grammond, P., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24287 · Cited by 101
Self-citationOrtiz-Gutiérrez, R. M., Cano‐de‐la‐Cuerda, R., Galán-del-Río, F., Diego, I. M. A., Palacios‐Ceña, D., & Miangolarra‐Page, J. C. (2013) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph10115697 · Cited by 100
Costs and quality of life of multiple sclerosis in the United Kingdom
Kobelt, G., Berg, J., Lindgren, P., Kerrigan, J., Russell, N., & Nixon, R. (2006) · The European Journal of Health Economics · doi:10.1007/s10198-006-0380-z · Cited by 99
Self-citationMultiple sclerosis, vitamin D, and HLA-DRB1*15
Handunnetthi, L., Ramagopalan, S. V., & Ebers, G. C. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e24124 · Cited by 98
Kinkel, R. P., Dontchev, M., Kollman, C., Skaramagas, T. T., O'Connor, P. W., & Simon, J. H. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.1426 · Cited by 97
Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis
Prosperini, L., Giannì, C., Leonardi, L., Giglio, L. D., Borriello, G., Galgani, S., Pozzilli, C., & Gasperini, C. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511417481 · Cited by 95
Symptomatic Epstein-Barr virus infection and multiple sclerosis.
Martyn, C. N., Cruddas, M., & Compston, D. A. S. (1993) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.56.2.167 · Cited by 94
Vascular comorbidities in the onset and progression of multiple sclerosis
Tettey, P., Simpson, S., Taylor, B. V., & van der Mei, I. A. F. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.10.020 · Cited by 93
Changes in the ascertainment of multiple sclerosis
Marrie, R. A., Cutter, G., Tyry, T., Hadjimichael, O., Campagnolo, D., & Vollmer, T. (2005) · Neurology · doi:10.1212/01.wnl.0000178891.20579.64 · Cited by 93
Self-citationEffects of early treatment with glatiramer acetate in patients with clinically isolated syndrome
Comi, G., Martinelli, V., Rodegher, M., Moiola, L., Leocani, L., Bajenaru, O. A., Carrá, A., Elovaara, I., Fazekas, F., Hartung, H.-P., et al. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512469695 · Cited by 93
The Diagnosis of multiple sclerosis
Poser, C. M. (2013) · Medical Entomology and Zoology · Cited by 92
Tedeholm, H., Lycke, J., Skoog, B., Lisovskaja, V., Hillert, J. A., Dahle, C., Fagius, J., Fredrikson, S., Landtblom, A., Malmeström, C., et al. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512463764 · Cited by 92
Utz, K. S., Hoog, J., Wentrup, A., Berg, S., Lämmer, A., Jainsch, B., Waschbisch, A., Lee, D.-H., Linker, R. A., & Schenk, T. (2014) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285614555335 · Cited by 92
Signori, A., Schiavetti, I., Gallo, F., & Sormani, M. P. (2015) · European Journal of Neurology · doi:10.1111/ene.12690 · Cited by 90
Self-citationModifiable factors influencing relapses and disability in multiple sclerosis
D'hooghe, M. B., Nagels, G., Bissay, V., & Keyser, J. D. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510367721 · Cited by 86
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
Edan, G., Kappos, L., Montalbán, X., Polman, C. H., Freedman, M. S., Hartung, H., Miller, D., Barkhof, F., Herrmann, J., Lanius, V., et al. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-306222 · Cited by 84
Kalinčík, T., Vaněčková, M., Týblová, M., Krásenský, J., Seidl, Z., Havrdová, E., & Horáková, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050101 · Cited by 83
Burden of a Multiple Sclerosis Relapse
Oleen-Burkey, M. A., Castelli‐Haley, J., Lage, M. J., & Johnson, K. P. (2012) · Patient · doi:10.2165/11592160-000000000-00000 · Cited by 82
Clinical concordance in sibling pairs with multiple sclerosis
Robertson, N. P., Clayton, D. G., Fraser, M., et al. (1996) · Neurology · doi:10.1212/wnl.47.2.347 · Cited by 82
The Differential Diagnosis of Multiple Sclerosis
Rolak, L. A., & Fleming, J. O. (2007) · The Neurologist · doi:10.1097/01.nrl.0000254705.39956.34 · Cited by 81
Requirement for safety monitoring for approved multiple sclerosis therapies: an overview
Rommer, P. S., Zettl, U. K., Kieseier, B. C., Hartung, H.-P., Menge, T., Frohman, E. M., Greenberg, B. M., Hemmer, B., & Stüve, O. (2013) · Clinical & Experimental Immunology · doi:10.1111/cei.12206 · Cited by 80
Multiple sclerosis relapses and depression
Moore, P., Hirst, C., Harding, K. E., Clarkson, H., Pickersgill, T. P., & Robertson, N. P. (2012) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2012.08.004 · Cited by 80
Bermel, R. A., Weinstock‐Guttman, B., BOURDETTE, D. N., Foulds, P., You, X., & Rudick, R. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458509360549 · Cited by 79
Wilson, L., Loucks, A., Bui, C. T., Gipson, G. R., Zhong, L., Schwartzburg, A., Crabtree, E., Goodin, D. S., Waubant, E. L., & McCulloch, C. E. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.06.030 · Cited by 75
Modica, C. M., Bergsland, N., Dwyer, M. G., Ramasamy, D. P., Carl, E. M., Zivadinov, R., & Benedict, R. H. B. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515579443 · Cited by 75
Epidemiology of multiple sclerosis: results from a large observational study in the UK
Jick, S. S., Li, L., Falcone, G. J., Vassilev, Z. P., & Wallander, M.-A. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7796-2 · Cited by 74
Atar, D., Birkeland, K., & Uhlig, T. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.128462 · Cited by 74
Reynolds, M., Johnston, J. M., Dodge, H. H., DeKosky, S. T., & Ganguli, M. (1999) · Neurology · doi:10.1212/wnl.53.1.228 · Cited by 72
High prevalence and no latitude gradient of multiple sclerosis in Norway
Berg‐Hansen, P., Moen, S., Harbo, H., & Celius, E. G. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514525871 · Cited by 71
Facilitating Medication Adherence in Patients with Multiple Sclerosis
Remington, G. M., Rodriguez, Y., Logan, D., Williamson, C., & Treadaway, K. (2013) · International Journal of MS Care · doi:10.7224/1537-2073.2011-038 · Cited by 71
Bergvall, N., Makin, C., Lahoz, R., Agashivala, N., Pradhan, A. K., Capkun, G., Petrilla, A. A., Karkare, S. U., McGuiness, C. B., & Korn, J. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088472 · Cited by 70
The Novo Group, Fernández, O., Fernández, V., Arbizu, T., Izquierdo, G., Bosca, I., Arroyo, R., García Merino, J. A., & de Ramón, E. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5560-1 · Cited by 69
Farias, S. T., Mungas, D., Reed, B., Carmichael, O. T., Beckett, L. A., Harvey, D. J., Olichney, J., Simmons, A. L., & DeCarli, C. S. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.03.017 · Cited by 69
Kane, R. L., Bever, C. T., Ehrmantraut, M. E., Forte, A., Culpepper, W. J., & Wallin, M. T. (2008) · Journal of Telemedicine and Telecare · doi:10.1258/jtt.2008.070904 · Cited by 68
Head size and cognitive ability in nondemented older adults are related
Tisserand, D. J., Bosma, H., van Boxtel, M. P. J., & Jolles, J. (2001) · Neurology · doi:10.1212/wnl.56.7.969 · Cited by 68
Comparative efficacy of switching to natalizumab in active multiple sclerosis
Spelman, T., Kalinčík, T., Zhang, A., Pellegrini, F., Wiendl, H., Kappos, L., Tsvetkova, L., Belachew, S. M., Hyde, R., Verheul, F., et al. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.180 · Cited by 64
Self-citationPatient perceptions of multiple sclerosis and its treatment
Gauthier, I., Seze, J. D., & Brudon (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s27038 · Cited by 63
Foley, J. F., Stoker, E., & Damal, K. (2013) · Biologics · doi:10.2147/btt.s53007 · Cited by 62
Cited by
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
New insights into the burden and costs of multiple sclerosis in Europe
Kobelt, G., Thompson, A., Berg, J., Gannedahl, M., Eriksson, J., the MSCOI Study Group, & Platform, T. E. M. S. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517694432 · Cited by 733
Self-citationDynamics of oligodendrocyte generation in multiple sclerosis
Yeung, M. S. Y., Djelloul, M., Steiner, E., Bernard, S., Salehpour, M., Possnert, G., Brundin, L., & Frisén, J. (2019) · Nature · doi:10.1038/s41586-018-0842-3 · Cited by 376
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
Baker, D., Marta, M., Pryce, G., Giovannoni, G., & Schmierer, K. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.01.042 · Cited by 289
Self-citationDalgas, U., Langeskov-Christensen, M., Stenager, E., Riemenschneider, M., & Hvid, L. G. (2019) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-019-1002-3 · Cited by 287
Metadata
- Authors
- Giovannoni, G., Butzkueven, H., Dhib-Jalbut, S., Hobart, J., Kobelt, G., Pepper, G., Sormani, M. P., Thalheim, C., Traboulsee, A., & Vollmer, T.
- Venue
- Multiple Sclerosis and Related Disorders
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 9
- Pages
- S5-S48
- ISSN
- 2211-0348 (ISSN-L)
- OpenAlex
- W2463810424
- Cited by
- 458
- References
- 252
- FWCI
- 24.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.